Susquehanna Fundamental Investments’s C4 Therapeutics CCCC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67,617	Closed	-$129K	–	518
2025 Q4	$129K	Hold	67,617	–	–	﹤0.01%	529
2025 Q3	$150K	Hold	67,617	–	–	0.01%	525
2025 Q2	$96.7K	Sell	67,617 -144,386	-68%	-$210K	﹤0.01%	698
2025 Q1	$339K	Buy	212,003 +103,339	+95%	+$308K	﹤0.01%	931
2024 Q4	$391K	Buy	+108,664	New	+$540K	0.01%	900
2024 Q2	$600K	Buy	129,801 +78,436	+153%	+$468K	0.01%	650
2024 Q1	$420K	Buy	+51,365	New	+$398K	0.02%	498
2023 Q4	–	Sell	-17,572	Closed	-$32.7K	–	115
2023 Q3	$32.7K	Hold	17,572	–	–	﹤0.01%	355
2023 Q2	$48.3K	Hold	17,572	–	–	﹤0.01%	623
2023 Q1	$55.2K	Sell	17,572 -14,924	-46%	-$87.9K	﹤0.01%	922
2022 Q4	$192K	Buy	+32,496	New	+$269K	﹤0.01%	1074

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna Fundamental Investments's CCCC Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 67,617 shares — an estimated $129K sold.

Susquehanna Fundamental Investments first reported a position in CCCC in Q4 2022 and held it in 11 quarters. The position peaked at $600K in Q2 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Susquehanna Fundamental Investments reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
Susquehanna Fundamental Investments sold 67,617 C4 Therapeutics shares in Q1 2026, an estimated $129K.
Susquehanna Fundamental Investments first reported a position in C4 Therapeutics in Q4 2022 and held it in 11 quarters.
Susquehanna Fundamental Investments's C4 Therapeutics position peaked at $600K in Q2 2024.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.